Researcher

Andre Esteva

Andre Esteva is an AI scientist whose work spans deep learning for skin-cancer diagnosis and cancer treatment. He earned undergraduate degrees in electrical engineering and pure mathematics at UT Austin in 2011 and pursued a Stanford PhD in computer vision; a 2017 paper he co-authored described a model that matched dermatologist accuracy on skin-cancer images. He co-founded contact-center AI company Cresta, held engineering roles at Google Research, Sandia National Labs and GE Healthcare, and led Medical AI at Salesforce Research before co-founding Artera, whose cancer tests use tissue images and clinical data to inform treatment. As of October 2026, he is Artera’s CEO and co-founder; TIME named him to the 2025 TIME100 Health list, and its prostate and breast cancer assays received EU CE marking in April 2026.

Now at
Artera
Works
88
Citations
28,013
h-index
28

Publication numbers from OpenAlex, as of 22 October 2026.

Timeline

  1. 2011

    Degrees at UT Austin

    He completes undergraduate degrees in electrical engineering and pure mathematics at UT Austin in December 2011, with highest honors.

  2. 2017

    Stanford’s AI Lab

    In 2017, he pursues a PhD in electrical engineering at Stanford and studies machine learning in Sebastian Thrun’s group within the Artificial Intelligence Lab of Computer Science.

  3. 2017

    Skin cancer classification

    In 2017, he co-authors the Nature paper “Dermatologist-level classification of skin cancer with deep neural networks.” Its model trains on lesion images and reaches accuracy comparable to board-certified dermatologists.

  4. 2017–2019

    Co-founding Cresta

    He joins Cresta as a co-founder in October 2017 and serves through January 2019. The company develops generative AI software for contact centers that helps customer support and sales agents.

  5. 2019–2021

    Medical AI at Salesforce

    From September 2019 to August 2021, he leads Medical AI at Salesforce Research; his engineering roles also include Google Research, Sandia National Labs, and GE Healthcare. Salesforce Research’s ReceptorNet deep-learning system predicts breast-cancer hormone-receptor status from H&E tissue images.

  6. 2025

    TIME100 Health

    In 2025, he joins the TIME100 Health list.

  7. April 2026

    EU CE marking

    In April 2026, he leads Artera as its prostate and breast cancer assays receive EU CE marking under the In Vitro Diagnostic Regulation.

  8. Since 2021

    CEO of Artera

    As of October 2026, he is CEO and co-founder of Artera, a role he starts in September 2021. Its cancer tests combine digitized histopathology images with patient clinical variables to assess cancer aggressiveness and potential treatment benefits.

Career

  1. Since 2021ArteraCEO and co-founder
  2. 2019–2021SalesforceLead, Medical AI
  3. 2017–2019CrestaCo-founder
  4. Google ResearchEngineer
  5. National Nuclear Security AdministrationEngineer
  6. GE HealthCareEngineer

Education

  1. From 2017Stanford UniversityPhD in electrical engineering
  2. 2011University of Texas at AustinUndergraduate degrees in electrical engineering and pure mathematics

Sources and credits

Photo: We have no published photo of Andre Esteva yet. Send us a free-licensed photo.

  1. Texas ECE alum Andre Esteva helps train a computer to identify skin cancer ece.utexas.edu. Checked 20 October 2026.
  2. Andre Esteva | ArteraAI artera.ai. Checked 20 October 2026.
  3. Dermatologist-level classification of skin cancer with deep neural networks cs.stanford.edu. Checked 20 October 2026.
  4. Andre Esteva andreesteva.com. Checked 20 October 2026.
  5. The creator of Google’s self-driving car project is now working to automate boring office functions cresta.com. Checked 20 October 2026.
  6. AI at Work: How Salesforce AI Could Make Therapeutic Decision-Making for Breast Cancer More Accurate, Affordable and Accessible salesforce.com. Checked 20 October 2026.
  7. Artera Secures CE Marking for Its AI Prostate and Breast Cancer Assays, Unlocking Global Expansion artera.ai. Checked 20 October 2026.